在渠道商高调发难药企的背后是医药流通行业艰难生存的现实“还在谈判中。”6月13日夜里近11点,南京医药执行副总裁滕学武还在谈判桌上。电话那头的他难掩疲惫。4月28日,南京医药股份有限公司宣布,开始停止从西安杨森公司购进任何品种的药品。要以“全面对话的方 Behind the high-profile channeling drug companies is the reality of the difficult survival of the pharmaceutical distribution industry. “The negotiations were still under way.” Nearly 11 o’clock on the night of June 13, Teng Xuewu, Nanjing Pharmaceutical’s executive vice president, was still negotiating on the table. He could hardly conceal his tiredness over the phone. On April 28, Nanjing Pharmaceutical Co., Ltd. announced that it has started to stop purchasing any variety of drugs from Xi’an Janssen Company. To "a comprehensive dialogue of the parties